PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Acta Psychiatr Scand. Author manuscript; available in PMC 2014 May 1.
Published in final edited form as:
PMCID: PMC4006272
NIHMSID: NIHMS570293

Antidepressant Use in Pregnancy: A Critical Review Focused on Risks and Controversies

Nancy Byatt, D.O., M.B.A., Assistant Professor of Psychiatry, Kristina M. Deligiannidis, M.D., Assistant Professor of Psychiatry and Obstetrics & Gynecology, Director, and Marlene P. Freeman, M.D., Associate Professor of Psychiatry

Abstract

Objective

Conflicting data have led to controversy regarding antidepressant use during pregnancy. The objectives of this paper are to: (1) review the risks of untreated depression and anxiety; (2) review the literature on risks of exposure to antidepressants during pregnancy; (3) discuss the strengths and weaknesses of the different study designs used to evaluate those risks; and, (4) provide clinical recommendations.

Method

MEDLINE/PubMed was searched for reports and studies on the risk of first trimester teratogenicity, post natal adaptation syndrome (PNAS), and persistent pulmonary hypertension (PPHN) with in utero antidepressant exposure.

Results

While some individual studies suggest associations between some specific major malformations, the findings are inconsistent. Therefore, the absolute risks appear small. PNAS occurs in up to 30% of neonates exposed to antidepressants. In some studies, PPHN has been weakly associated with in utero antidepressant exposure, while in other studies there has been no association.

Conclusion

Exposures of concern include that of untreated maternal illness as well as medication exposure. It is vital to have a careful discussion, tailored to each patient, which incorporates the evidence to date, and considers methodological and statistical limitations. Past medication trials, previous success with symptom remission, and women’s preference should guide treatment decisions.

Keywords: Antidepressant, In utero, Teratogenicity, Post natal adaptation syndrome, Persistent pulmonary hypertension

INTRODUCTION

During the reproductive years a significant proportion of women experience depressive and anxiety disorders (1). Approximately 18.4% of women suffer from antenatal depression, and as many as 19.2% of mothers develop a depressive disorder within several weeks of delivery (2). Anxiety disorders are also common, with a prevalence rate of 21.7% during the 3rd trimester of pregnancy, and 11.1% during the first 3 postpartum months (3, 4).

Untreated depression and anxiety during pregnancy negatively impacts mother and fetus/child. Women are more likely to experience inadequate maternal weight gain (5) and abuse substances (6). Depression in pregnancy is also associated with preeclampsia, preterm birth (7, 8) (9) (10), increased risk for delivery of a low birth weight infant (11), elective termination of the pregnancy (12), postpartum depression (13), and anxiety. Depression is associated with fetal distress (14) and an increased risk of neonatal care unit admission and caesarian delivery (15).

Postpartum depression can negatively impact child development and has been associated with difficult infant and childhood temperament (16, 17) and attachment insecurity (16). Maternal depression may also lead to emotional and functional disability in children including cognitive delays (18), behavioral problems (16), and difficulties with social interaction (19). Children of depressed mothers are at increased risk of developmental delay, impaired language development, and lower IQ scores (20, 21). The impact of maternal depression has effects beyond infancy, as one-third of school-aged children of depressed mothers suffer from depressive, anxiety or disruptive disorders (22). Effective treatment of maternal depression mitigates this negative impact (23). Perinatal depression can also be fatal; maternal suicide accounts for up to 20% of postpartum deaths in depressed women (24).

Stress and anxiety during pregnancy influence maternal behavior and birth outcomes: maternal tobacco smoking, caffeine consumption, poor nutrition and exercise, preterm labor, preterm birth and low birth weight are associated with prenatal anxiety (25). Antenatal anxiety may increase the risk of childhood developmental and psychiatric disorders. It may adversely affect infant emotional development (26) and has been associated with reductions in gray matter density in young children (27). Treatment of perinatal depressive and anxiety disorders is of paramount importance to mitigate these risks. Despite the risk of relapse to depressive episodes and anxiety and associated adverse effects, women are likely to stop antidepressant treatment during attempts to conceive or pregnancy (28, 29).

Due to conflicting reports in the literature on the risk of first trimester teratogenicity, post natal adaptation syndrome (PNAS), and persistent pulmonary hypertension (PPHN) with in utero antidepressant exposure, a review of these topics is of great clinical importance. In this review, selected topics of controversy regarding antidepressant use in pregnancy are presented, in order to provide clarification during clinical decision making and risk/benefit assessment and discussion. A review of all possible outcomes is beyond the scope of this paper. Although not reviewed in this article, there are associations among antidepressant in utero exposure and measures of birth outcome, including an increased rate of spontaneous abortion (30-35) (36-39), low birth weight (35, 40, 41), and reduced gestational age or preterm birth (35, 40, 42-44) in depressed women exposed to antidepressants. Recent studies have raised questions about possible associations with antidepressant use in pregnancy, including autism (45) and effects on long-term neurocognitive development (46). While all associations with in utero exposure are important, we limited our review to topics that have become the main controversies in antidepressant use during pregnancy in recent years.

Aims

The purpose of this review is to: (1) review the risks of untreated depression and anxiety; (2) review the literature on risks of exposure to commonly used antidepressants during pregnancy; (3) discuss the strengths and weaknesses of the different study designs used to evaluate those risks; and, (4) provide clinical recommendations.

METHODS

A search was done for the English-language literature indexed on MEDLINE/PubMed for the period between 1966 and 2012 using the following key terms: antidepressant, SSRI, SNRI, noradrenergic and specific serotonin antidepressant (NaSSA), NRI, fluoxetine, paroxetine, sertraline, citalopram, escitalopram, fluvoxamine, venlafaxine, mirtazapine, reboxetine, duloxetine, bupropion, trazodone, nefazodone, and vilazodone in association with antenatal depression, maternal, pregnancy, prenatal exposure, malformation, in utero exposure, neonatal complications, gestational, neonatal health, neonatal outcome, birth outcome, persistent pulmonary hypertension, birth defects and congenital heart defect. To determine whether other relevant articles were not identified in the initial search, all articles were cross-referenced. Original observational studies, case reports and case series were included.

RESULTS

First Trimester Exposure: Is There Evidence of Teratogenicity?

In the U.S., approximately 1 in every 33 infants (3%) is born with a major birth defect (47). Major birth defects or malformations typically require medical or surgical intervention for a structural or functional abnormality. Antidepressants that affect serotonergic tone could putatively increase the incidence of congenital malformations because serotonin is important in aspects of early embryonic development that impact development of the neural tube, branchial arch and heart.

Despite the high prevalence of birth defects overall in the population, each specific type of major birth defect is generally rare, and studies that are inadequately powered or controlled may overestimate risk and association. For example, of the major birth defects studied in association with antidepressant use, omphalocele occurs in 1 per 5,386 births, gastroschisis occurs in 1 per 2,229, anencephaly 1 in every 4,859, and craniosynostosis in 4-10 per 10,000 births in the general population (47). While congenital heart disease is relatively common (48, 49), studies examining the effects of drug exposure should ideally use the rate of unexposed infants with identical ascertainment methods as a comparison rate for the malformation(s) under study, rather than the 1% incidence of congenital heart disease (48, 49) in the general population which makes interpretation of findings difficult.

Different methodologies have been used to study the risks of teratogenicity with antidepressant use in pregnancy. Some use retrospective case-control studies, which carry the risk of recall bias and large non-response rates. Other prospective controlled studies, often performed in teratology information centers, use detailed drug use information in a small number of women. A final type of study uses data from drug registries and administrative data bases, which carry the risk of exposure misclassification given that it is not clear whether women who purchased the drug took it as prescribed. When they recently compared interview data with data from a prescription registry, Kallen et al. found the most valid results are obtained through prospective interview data on drug use. For prescription data, they recommended avoiding the use of prescriptions given earlier than 1 month before the last menstrual period due to the increased percentage of women who did not use the medication in pregnancy (50).

Across all study types, the risks of the underlying untreated disorder and other associated confounding factors are rarely taken into account. The strategy of using depressed women without drug treatment as a comparison may not be adequate given the likelihood that illness severity co-varies with medication use. Comparisons of different SSRI effects may also be complicated by the fact that this class of medications is used for many conditions other than depression, including anxiety disorders (51). SSRI preference may also differ according to indication, and prescribing patterns may differ between populations. In order to control for maternal illness severity, Oberlander et al. used a propensity score method that allowed them to control for maternal illness severity and other characteristics that impact neonatal outcomes. Unfortunately, even with their large population level data set, propensity score matching led to a reduced sample size for comparison groups (52).

The use of different study designs and limitations of each may explain why findings of malformations are inconsistent. At present, data are difficult to interpret because it difficult to differentiate whether adverse outcome are associated with underlying illness, the medication itself or other unknown factors associated with either or both.

Selective Serotonin Reuptake Inhibitors (SSRIs)

Prior to 2005, studies had not suggested an increased risk of major congenital malformations with in utero exposure to SSRIs (35, 36, 43, 53-59). These studies, as well as those since, were generally limited by insufficient power, confounding variables, concerns with the method of birth outcome classification and limited exposure information (60). Over the past several years, a number of studies have found associations between specific SSRIs and malformations, although the findings are inconsistent across studies, making their interpretation difficult. A teratogen would be expected to cause a similar type of malformation consistently across studies. While this has not been the case with SSRIs, sporadic reports have generated concerns.

Since 2005, the data have been conflicting and inconsistent (61) with regard to whether individual SSRIs are associated with an increased risk of congenital malformations. Discrepant findings have fueled confusion, and it is unclear whether un-replicated results represent true associations. One example of conflicting findings are the retrospective case-control studies by Alwan et al. and Louik et al. which linked the use of SSRI drugs to rare malformations. Both studies carry a risk for recall bias and have a high rate of non-responders (60, 62). Other studies have other methodological limitations, for example, Wogelius et al. (63) identified malformations from discharge diagnoses in women with and without intrauterine SSRI exposure. Examining physicians were aware of SSRI exposure which may have increased vigilance during exams, and led to surveillance bias and overestimation of risks due to the identification of less serious malformations, e.g., mild cardiac defects that would not otherwise have been identified. Other studies are so small that they lack statistical power to detect anything but extreme risk increases that are unlikely to occur with SSRI exposure.

A small increased absolute risk of rare defects such as omphalocele, anencephaly, craniosynostosis, (60), cystic kidney and congenital heart defects (51, 64-66) has also been reported. Importantly, specific patterns of congenital malformations have not been demonstrated with SSRIs across studies, and teratogenicity is usually determined by a consistent risk and pattern of malformation. Among the SSRIs, paroxetine has become the most complicated in terms of reported risks and recommendations for use in pregnancy.

Paroxetine

In 2005, a small study performed by GlaxoSmithKline suggested an increase in cardiac malformations in infants exposed to paroxetine in utero compared with controls. As a result, GlaxoSmithKline modified the prescribing information to include a warning regarding the risk of cardiac malformations with antenatal paroxetine exposure. This study was not peer-reviewed or published, but was presented to the U.S. FDA and cited elsewhere (67). As this recommendation was based on non-peer-reviewed, unpublished data, and a relatively small sample size, its findings are difficult to interpret (68). Since then, multiple studies (41, 51, 60, 66, 69-73), although not all (65, 74), have found an association between prenatal paroxetine exposure and an increased risk of congenital malformations, yet the causality and magnitude of that risk are unclear.

A recent meta-analysis based on research prior to 2006, found that paroxetine was associated with 1.7 fold risk increase of cardiac malformation (71). A later review, however, concluded that is not practical to use a meta-analysis to examine the safety of paroxetine in pregnancy given the limitations in the methodology of the published studies (75). Another meta-analysis that examined 37 studies from January of 1992 through September 2008, provides further evidence of an increased risk of major congenital malformations with paroxetine exposure. The authors concluded that first-trimester paroxetine exposure is associated with an increased prevalence of combined cardiac defects (prevalence odds ratio (POR) = 1.46%; 95% CI 1.17-1.82) and aggregated defects (POR=1.24; 95% CI 1.08-1.43) (70).

Other SSRIs

Specific individual studies have found malformations associated with specific SSRIs as isolated reports. These include hypertrophic stenosis (76), congenital heart defects, and other major abnormalities (41, 65, 73, 77) with fluoxetine, omphalocele (62, 77-79) and cardiac septal defects (62, 77, 79) with sertraline, and omphalocele (62, 77-79), congenital heart defects (62, 77, 79), and neural tube defects (73) with citalopram. Other studies however, have not suggested an association between fluoxetine (62, 64, 69, 77-84), sertraline (41, 51, 69, 73, 80-84), or citalopram (41, 80-82, 84) and major congenital abnormalities. While the data are very limited, escitalopram has not been associated with risk of major malformation (62, 73, 81, 85).

Meta-analyses

When interpreting this data, it is imperative to consider meta-analyses, because the power of individual studies may not be adequate and large numbers of subjects are needed to demonstrate association with congenital malformations. Five meta-analyses have investigated the risk for major malformations in association with antidepressant use during pregnancy. Four of these studies found no statistically significant increased risk of major malformations in the first trimester of pregnancy (31, 86-88). The fifth meta-analysis found an increased risk of cardiac malformations in infants exposed to paroxetine in the first trimester (71).

In summary, paroxetine and other SSRIs have not consistently been demonstrated to be associated with particular birth defects. Paroxetine use during early pregnancy has been the most controversial, as it has been associated with an increased risk of overall major malformations, particularly atrial and ventricular septal defects in several studies (51, 60, 66, 69, 72), but assessments of large databases have not supported this finding (65, 74).

Serotonin-norepinephrine reuptake inhibitors (SNRIs), Norepinephrine reuptake inhibitors (NRI) and other antidepressants

Compared to the SSRIs, there are fewer reports on the reproductive safety profiles of other antidepressants. While the available evidence is extremely limited, studies examining venlafaxine, duloxetine, nefazodone, and mirtazapine do not suggest an increased risk of congenital malformations (39)(81)(89)(90). An increased risk of left outflow tract heart defects has been inconsistently demonstrated in association with bupropion. Overall, the limited studies have shown reassuring, but not definitive data regarding the reproductive safety of venlafaxine, trazodone, mirtazapine, and bupropion.

Bupropion

Bupropion has efficacy for smoking cessation, and tobacco use is associated with birth complications. Understanding the safety of bupropion in pregnancy is important as it may be a potential treatment option for women with depression and nicotine dependence. In 1997, GlaxoSmithKline established a Bupropion Pregnancy Registry and by March 2008, 3.6% and 1.3% of infants exposed to bupropion were reported to have congenital abnormalities and congenital heart defects, respectively. Congental heart defects were found in both retrospective and prospective reports (91), raising concern that first timester bupropion exposure might increase the risk of congenital heart defects. The first prospective study on bupropion use in pregnancy did not demonstrate an increased risk of major malformation with bupropion exposure, however, the sample was small with only enough power to detect a 5-fold increased risk (37). A retrospective case-control study that examined the risk of bupropion exposure 1 month prior to conception until 3 months after conception found that exposed infants were more likely to have left outflow tract heart defects, but not other defects (OR=2.6; 95% CI 1.2-5.7) (92). Another case-control study did not find an increased risk of congenital malformations when they compared first trimester bupropion exposure to: (1) first trimester exposure to other antidepressants; and, (2) bupropion exposure outside the first trimester (93). Other studies (37) (92) are reassuring as they do not demonstrate an increased risk of congenital malformations following exposure to bupropion during pregnancy. Even with the the possible increased of congenital heart defects (91, 92), the absolute risk of a congenital heart defect remains low at 2.1/1000 births in exposed infants (92) when compared to the estimated prevalence of 0.82/1000 births in the general population (49).

SNRIs and other non-SSRI antidepressants

There are a very limited number of studies examining SNRIs (such as venlafaxine and duloxetine). A large prospective cohort study that included the SNRI venlafaxine, and other non-SSRI antidepressants -mirtazapine, nefazadone, bupropion and trazodone - found that the prevalence of cardiac malformations was well below the prevalence rate at 0.6% in the antidepressants as a group (81). Data obtained from the Swedish Medical Birth Registry also do not suggest an increased risk of congenital malformations after exposure to SNRI/NRIs. However, due to small sample size it only would have detected a marked teratogenic effect (89).

Mirtazapine

A prospective, comparative study that examined whether exposure to mirtazapine during organogenesis increased the rate of major malformations, found that mirtazapine was not associated with an increased risk of major malformation (39).

Trazodone/Nefazodone/Vilazodone

Data on trazodone and nefazodone are limited with the exception of a multi-centre prospective controlled study which found that trazodone and nefazadone did not increase the rates of major malformation above the baseline (90). A literature review did not reveal any data on vilazodone.

Summary

Recently, the safety of SSRIs in pregnancy has been challenged by data from large population-based studies. Reports are difficult to interpret due to the lack of consistent findings and the inability to assess cause and effect from association studies. Most reports do not take into account the underlying psychiatric condition and variables that may not be controlled for that would differ between groups being compared. While some individual studies suggest associations between SSRIs and some specific major malformations, the findings are inconsistently observed, therefore the absolute risks appear small. While the limited available data suggest a possible association between bupropion and congenital heart defects (91, 92), the absolute risk appears low. Although the very limited studies examining SNRIs have been reassuring, further investigation is needed before the risks associated with their use may be fully understood.

Later Pregnancy Controversies

Post Natal Adaptation Syndrome (PNAS)

All SSRIs cross the placenta, carrying the potential to increase serotonin concentrations in the developing fetus. Increased serotonin concentrations may impact fetal cardiovascular, respiratory and neurological development, which all involve serotonin. Premature neonates may be more susceptible to PNAS given their immature lung and central nervous systems.

Since PNAS was first noted in 1973 (94), exposure to antidepressants during late pregnancy has been associated with infant irritability, abnormal crying, tremor, lethargy, hypoactivity, decreased feeding, tachypnea, and respiratory distress (95-99). As data emerges, this cluster of symptoms is increasingly referred to as PNAS. It has also been referred to as “neonatal behavioral syndrome” or “poor neonatal adaptation syndrome” with studies focusing on a collection of symptoms including irritability, tachypnea, hypothermia, and hypoglycemia (96, 100-102). Clinical signs and symptoms usually develop from birth to days after delivery and are time-limited. While they usually resolve within days or weeks of delivery (95), symptoms have been reported to last as long as 6 weeks (103). Severity and length are impacted by multiple factors including dose, timing and duration of exposure and SSRI pharmacology including half-life, presence of active metabolites, and maternal and infant hepatic cytochrome P450 isoenzyme genotype, among others (104).

Different methodologies have been used to examine the relationship between PNAS and antidepressants. Databases of adverse drug event reports have the advantage of being able to detect effects too rare to be detected in clinical trials. Similar to case reports, however, databases of adverse drug reaction reports are limited by lack of incidence rate determination, underreporting and reporter bias (95). The identification of PNAS symptoms related to antidepressant exposure is also complicated by the challenge of determining whether the symptoms are due to maternal illness or medication exposure (105). Important considerations in evaluating the data include: 1) whether systematic assessments of infant were conducted, 2) whether appropriate control groups were included in the study, 3) whether raters of the infants were blinded to antidepressant exposure, 4) whether maternal diagnosis or symptoms were taken into consideration, and 5) whether other confounding variables may contribute to neonatal symptoms.

Numerous mechanisms have been proposed for PNAS including serotonin toxicity (104), overstimulation of serotonin (101), and infant genotype (106). Many PNAS symptoms overlap those found in adult SSRI discontinuation syndrome, cholinergic overdrive and serotonin syndrome. Several case reports note infant toxicity after in utero exposure to paroxetine (106), and fluoxetine (97, 107-109). Several of those reports note elevated infant serum levels, supporting toxicity as the cause (97, 107, 108, 110). Other reports document discontinuation symptoms following in utero antidepressant exposure (110), specifically with sertraline (111), paroxetine (98-100, 112, 113), and venlafaxine (114).

In 1996, Chambers et al published the first cohort study examining PNAS and found that late pregnancy exposure to fluoxetine was associated with an increased special care nursery admission rate when compared to exposure earlier in pregnancy (35). A similar study that retrospectively compared exposure to fluoxetine early and late in pregnancy found an increased risk of special care nursery admissions after late pregnancy exposure to fluoxetine (115).

Another study that prospectively compared neonatal complications in infants found that third trimester paroxetine exposure had a high rate of neonatal complications compared to controls (22% vs. 5.5% respectively) (102). Using the same definition as Chambers et al, Oberlander et al found that thirty percent of infants exposed to SSRI alone or in combination with clonazepam showed symptoms of poor neonatal adaptation, 25% and 39% respectively (104). Another hospital based cohort study found PNAS in 30% of infants exposed to SSRIs (116). This rate of 30% is higher than found by Costei et al (22%) (102), and Hendrick et al (10.5%) (55) but very similar to that found by Chambers et al (31.5%) (35) and Oberlander et al (30%) (104). The data collected by Costei may not represent the true rate as data were collected later after delivery and cases may have been missed. A retrospective chart review study reported a higher rate of behavioral signs (77.6%) in SSRI exposed infants compared to 41% of the nonexposed (117).

In a prospective comparison study, using cord blood levels of 5-Hydroxyindoleacetic acid (5-H1AA) and a modified Serotonin Syndrome Scale, infants exposed to citalopram or fluoxetine in late pregnancy had lower Apgar scores and more serotonergic symptoms than infants not exposed (101). Other prospective studies have also found that third trimester exposure to antidepressants is associated with PNAS symptoms (118) and greater special care nursery admission rates (119). While it lacked statistical significance, a prospective controlled cohort noted a trend for increased risk of PNAS symptoms in infants exposed to antidepressants in the second and third trimester. Mild symptoms may have been underreported due to recall bias during data collection interviews with mothers (120).

SSRIs and SNRIs may both cause PNAS symptoms. A prospective observational study comparing placental transfer and neonatal effects of SSRI and SNRI (venlafaxine) exposure in pregnancy to non-exposed matched controls found that both SSRIs and venlafaxine transferred across the placenta and were associated with PNAS symptoms (121). An analysis of the World Health Organization adverse events database reported 94 cases of PNAS after in utero exposure to SSRIs and venlafaxine. PNAS symptoms in infants were noted after maternal fluoxetine, citalopram or paroxetine exposure (100). However, the total number of women using these medications was not reported, so the incidence of neonatal symptoms was not possible to ascertain.

In 2004, the FDA suggested (122) providers consider tapering antidepressants in the third trimester. While discontinuation is intuitive if antidepressants are associated with neonatal symptoms, this recommendation did not receive formal clinical study prior to its release. Since this recommendation, Warburton (2010) and colleagues assessed babies of mothers who were not exposed to antidepressants in the last 14 days of pregnancy compared to those who were not exposed and factored in maternal psychiatric symptoms and other possible cofounding variables into their analysis. After accounting for confounding variables, there was no difference in PNAS among women exposed to antidepressant in the last 14 days of pregnancy when compared to those who were not. However, the total number of women using these medications was not reported, so the incidence of neonatal symptoms was not possible to ascertain (52). This study was also limited by the inclusion of subjects on fluoxetine, which may have been in the subjects’ system given its long half-life of two weeks.

PNAS appears to be multifactorial in nature, with late pregnancy antidepressant use accounting, in part, for neonatal symptoms. It is important to consider that maternal anxiety has also been associated with changes in infant behavior and self-regulation (123). Exposure to antidepressants in pregnancy, regardless of timing, has been associated with PNAS. While the available evidence is conflicting, the overall data suggests that PNAS can occur in neonates exposed to SSRIs and SNRIs, yet have most often been reported after exposure to paroxetine, fluoxetine and venlafaxine (84, 120).

Persistent pulmonary hypertension of the newborn (PPHN)

Pulmonary hypertension is a normal and required state for the fetus in utero because the placenta, as opposed to the lung, is responsible for gas exchange. At birth, the lung replaces the placenta as the primary site of gas exchange, and there is a rapid drop in pulmonary vascular resistance and a resultant increase in pulmonary blood flow. Multiple chemical pathways are responsible for this cardiopulmonary transition (124).

PPHN can result whenever cardiopulmonary transition does not occur. PPHN is a rare disorder that occurs in approximately 1-2 per 1000 births (125). Reduced length of gestation and premature birth has been associated with increased risk of PPHN (121). Infants with PPHN present within twelve hours of birth with cyanosis and mild respiratory distress and can develop severe respiratory failure requiring intubation and mechanical ventilation (126). Even with therapy, PPHN can be fatal in approximately 10-20% of cases (127), depending upon the etiology (128). Approximately 25% of infants with moderate to severe PPHN will demonstrate significant neurodevelopmental impairment at 12-24 months (129).

Respiratory insufficiency is one symptom of PNAS and may represent the presence of a mild form of PPHN and not PNAS, per se (130, 131). It is not certain that SSRIs are associated with the development of PPHN, but there is some evidence that longer periods of in utero SSRI exposure may be associated with increasing risk, and severity, of neonatal respiratory complications (132). How SSRIs may affect neonatal respiratory complications is under investigation. The accumulation of SSRIs in the lungs may result in high circulating levels of serotonin which, through its vasoconstrictive effects, increases pulmonary vascular resistance and may cause proliferation of smooth-muscle cells in the fetal lung (133), but not all studies have found elevated serotonin levels (134). Another possible mechanism may involve the inhibitory effect of SSRIs on nitric oxide synthesis, an essential vasodilator which regulates vascular tone (135) but other studies do not support that hypothesis (134). Importantly, through unidentified mechanisms, depression and the use of SSRIS during pregnancy have been associated with a reduced length of gestation and increased risk of premature birth (84) which itself is associated with an increased risk of PPHN. Additionally, genetic factors contribute to the risk of developing PPHN (128). Functional polymorphisms in the serotonin transporter promoter region may modulate the risk of PPHN in both adults (136) and infants with in utero exposure to SSRIs (128, 137).

In 1996, Chambers and colleagues first reported that late in utero exposure to fluoxetine was associated with an increased risk of PPHN when compared to first trimester exposure (2.7% vs. 0%), especially when compared to the prevalence found in the general population (0.07% - 0.10%) (35). A subsequent case-control study found that SSRI use after the 20th week of pregnancy was significantly associated with PPHN (adjusted odds ratio (AOR) = 6.1), but use of SSRIs or other antidepressants prior to 20 weeks gestation was not (138). A retrospective analysis of data from the Swedish Medical Birth Register also found an association between PPHN and maternal SSRI use during early pregnancy (relative risk (RR)=2.4) and late pregnancy (RR=3.6), though the absolute risk was small (139). This group’s most recent analysis which also included tricyclics, monoamine oxidase inhibitors, SNRIs and other antidepressants demonstrated an increased relative risk of PPHN for antidepressant exposure in early pregnancy (RR=2.30), for later exposure (RR=2.56) and for both early and later exposure (RR=3.44) (41).

Most of the above studies (41, 140, 141) restricted their analyses to infants delivered after 34 completed weeks gestation since shorter gestation is associated with an increased risk of PPHN. A recent population-based cohort study used national health register data demonstrated an increased risk of PPHN associated with SSRI prescription after 20 weeks gestation and before 8 weeks gestation (142). The risk of PPHN associated with exposure to individual SSRIs were of a similar magnitude, suggesting a class effect. This study restricted their analyses to infants delivered after 33 weeks gestation and was the largest completed study of the relationship between in utero SSRI exposure and PPHN.

Other studies have suggested no association between antidepressant use during pregnancy and PPHN. Two studies (143) (144) compared the prevalence of PPHN among infants whose mothers were exposed to antidepressants in the third trimester of pregnancy compared to infants not exposed and did not find any difference. The Wichman et al. study (144) is limited by a lack of delineation between women treated in late pregnancy and during the first trimester. Because late trimester use has been identified as a possible risk factor for PPHN, the inclusion of women who were treated in the first trimester may have contributed to the negative finding. Additionally, the small size of both of these studies makes it likely that a possible association would have been missed. Most recently a case-controlled study of 11,923 births, including 20 cases of PPHN, demonstrated an increased risk of PPHN with cesarean delivery prior to the onset of labor (OR=4.9) but not with SSRI use during the second half of pregnancy (145).

In 2006, based on data from the Chambers et al study, the FDA published a Public Health Advisory regarding an increased risk of PPHN associated with the use of SSRIs after the 20th week of pregnancy. This advisory resulted in changes to drug labeling to include a risk of PPHN with the use of antidepressants during late pregnancy. In December 2011, the FDA released a Drug Safety Communication (146) which stated that there is insufficient evidence that antidepressant exposure during pregnancy causes PPHN. This recent statement is an accurate reflection of the current literature which has reported either a small association between PPHN and maternal antidepressant use during pregnancy or no association.

Although studies have also reported an association between mode of delivery and PPHN (140, 141, 147-149), several were small and lacked control groups. Studies which have investigated the role of cesarean delivery and the risk of PPHN are limited because it is not clear whether the risk of PPHN is increased secondary to the mode of delivery or intrauterine fetal distress.

CLINICAL IMPLICATIONS AND DISCUSSION

The treatment of women during pregnancy is complex and clinical decisions should be based on the risks, benefits and alternatives to psychopharmacological treatment. All risks need to be considered, including those of untreated maternal psychiatric illness and the known and unknown potential risks of psychotropic medication. In order to provide optimal clinical care to women and their developing child, it is imperative to consider risks of treatment in the context of illness severity, consequences of no treatment and under-treatment and individual treatment preferences.

Interpreting a Conflicting Evidence Base

Clinicians face the challenge of interpreting an expanding and sometimes controversial evidence base. Comparing the available studies is difficult due to methodological weaknesses and differences in study design, outcome measures and exposure (72). This underlines the inherent and varying difficulties conducting epidemiological studies of this nature. In such a complicated area of study, no individual study is definitive. Statistical significance does not necessarily translate into a valuable clinical or epidemiological finding. For example, an OR of 1.2 compared to 1.7 may be statistically significant, yet not important from an epidemiological or clinical perspective.

The current evidence for malformations is limited because of inconsistent findings and limited methodology of the published studies (150). Few studies have controlled for maternal illness and therefore do not take into account whether reproductive outcomes are due to maternal illness or antidepressant exposure. Many studies also group malformation types together in order to detect a difference in risk. For example, some studies have grouped together all septal defects or congenital heart disease, encompassing a variety of birth defects and a range of severity. As a result, it is not known whether or not the reported increased risk for cardiac defects is for minor, moderate or severe forms, which each carry varying medical risks to the infant. Larger sample sizes are required to improve identification of particular teratogenicpatterns, so that specific birth defects associated with antidepressants can be isolated consistently and reproduced across studies. While the large studies that do not show evidence of teratogenicity are reassuring, the literature also contains a number of studies that suggest concerns.

The current evidence base for PNAS also has limitations in that it does not: (1) systematically assess infants; (2) use appropriate control groups; (3) use blind raters of the neonates; and, (4) take into account maternal diagnosis or symptoms or other confounding variables. Despite these limitations, these study findings vary less than that of the teratogenicity or PPHN studies, and therefore more strongly suggest an association between antidepressant use in pregnancy and neonatal behavioral symptoms.

Similarly, the PPHN literature is limited by small and/or uncontrolled studies. There are other reported risk factors, including race, method of delivery, obesity, asthma, and diabetes (141) that many studies do not take into account. While the PPHN literature is inconclusive, the available evidence reports either a small association between PPHN and maternal antidepressant use during pregnancy or no association.

Clinical Importance of Results

Given the inconclusive evidence, it is vital to have a careful discussion tailored to each patient that incorporates the evidence to date on the risks and benefits of antidepressant use in pregnancy. We recommend educating women about the risks of exposure to antidepressants throughout pregnancy, which should include the U.S.Food and Drug Administration categorization. Unfortunately, the U.S. FDA antidepressant risk categorization is limited, and does not adequately inform the decision making process. The limitations of this system include lack of a requirement for systematic human data, lack of clear differentiation between pregnancy categories, lack of incorporation of risks of the maternal illness and potential benefits of the medication. Newer drugs are usually much more poorly studied in human pregnancy, as little human data are required before a drug comes to market. Therefore, health care providers and patients who rely on the U.S. FDA categories may receive an oversimplified and often inaccurate assessment of the knowledge base regarding a specific medication in human pregnancy. Despite numerous studies, information regarding possible teratogenicity of antidepressants has not been updated since an FDA public health advisory in 2005 was released concerning paroxetine and the possible associated risk of increased cardiac malformations. The FDA is currently working on risk categorization that will include more meaningful and useful information to clinicians (151). However, with the current limitations of the FDA categories, it is crucial to incorporate the current research literature into the decision making and informed consent process.

Translating Results into Clinical Practice

We recommend weighing the risks and benefits of treatment with antidepressants during pregnancy while carefully considering the risk of untreated illness. What poses a greater risk: exposure to untreated illness or the antidepressant? If the benefits of treatment outweigh the risks, then the medication should be prescribed based on an individualized risk/benefit assessment and discussion. Past medication trials and previous success with symptom remission and women’s preference should guide treatment decisions. In order to avoid exposure to more than one antidepressant or undertreated illness one should choose a medication with known efficacy for individual women. The goal of treatment should be to maximize non-medication evidence based treatments, such as specific forms of psychotherapy, and remission of the maternal symptoms, with judicious use of pharmacotherapy when indicated.

Unless there is a reason to use another class of antidepressant, SSRIs are generally considered first-line in pregnancy. SSRIs, are well characterized, and even though risks have been reported, the preponderance of data is reassuring. It makes less sense to preferentially use a medication with less available human data. When selecting an antidepressant for a pregnant woman who has not had past medication trials, many providers prefer fluoxetine because of the amount of data available and lack of long term developmental sequela in children (152). A current response or history of a positive response to medication should help determine which medication to continue or initiate. The benefits of discontinuining an effective medication often do not outweigh the risks of relapse or of exposing mother and fetus to a second antidepressant medication during pregnancy.

In order to maximize treatment of depression and minimize risks of maternal and fetal exposure to antidepressants and untreated depression, women should receive the minimal effective dose of an antidepressant. The increased dose requirements across gestation (153) (154) should be considered and weighed against the risks when determining the minimal effective dose. It is also important to avoid under-treatment as residual depression and medication exposure represent dual exposures for the fetus.

Polypharmacy with multiple psychotropic medications should also be avoided, unless there is a clear indication for the use of multiple pharmacotherapies. Some studies suggest that the use of SSRIs in combination with benzodiazapines may increase the risk of congenital heart malformations (77) and PNAS (104). Another study did not demonstrate an increased risk of congenital malformations after exposure to multiple antidepressants (82). It is important to consider that approximately 50% of pregnancies are unplanned and many women enter the first trimester on several medications. For example, a positive response to taking two antidepressants concurrently may indicate that the risk of relapse with discontinuation of either outweighs the risk of polypharmacy.

Despite the FDA’s suggestion in 2004 (122) that providers consider tapering antidepressants in the third trimester, there no evidence suggesting this approach reduces the incidence of PNAS or improves infant outcomes. It also carries the risk of precipitating relapse or postpartum depression, particularly in high-risk individuals (52, 95).

Individualized treatment recommendations or plans should aim to diminish both the risk of exposure to untreated illness and the antidepressant. Exposure to untreated illness can be mitigated by preconception counseling, psychoeducation regarding risks and benefits of treatment and no treatment, close clinical monitoring, and a careful treatment plan tailored to the each woman (155). The risks associated with antidepressant use can be mitigated by using antidepressants with reassuring human data, using the minimal effective dose and avoidance of polypharmacy. Outcomes for mother and child can be optimized by the utilization of multidisciplinary approach that takes into account risks of treatment and no treatment and each woman’s preferences for treatment. This can be accomplished by a careful discussion, tailored to each patient, which incorporates the evidence to date and considers methodological and statistical limitations. Past medication trials, previous success with symptom remission, and women’s preference should guide treatment decisions.

Table I
Maternal use of antidepressants and the risk of congenital defects
Table II
Maternal use of antidepressants and the risk of post natal adaptation syndrome(PNAS)
Table III
Maternal use of antidepressants and the risk of persistent pulmonary hypertension of the newborn (PPHN)
TABLE IV
Results Summary
TABLE V
Clinical Points of Emphasis

SUMMATIONSCONSIDERATIONS
No single type of malformation has been
consistently observed across studies with
any commonly used antidepressant. Some
individual studies suggest associations
between particular SSRIs and specific birth
defects.
SSRIs remain the most studied
antidepressants in pregnancy. Less data are
available for SNRIs, mirtazapine,
nefazodone, trazodone and vilazodone.
Post natal adaptation syndrome (PNAS),
occurs in up to 30% of neonates exposed to
antidepressants in late pregnancy.
The current evidence base is limited by
data that do not: (1) systematically assess
infants; (2) use appropriate control groups;
(3) use blind raters of the neonates; (4) take
into account maternal diagnosis or
symptoms or other confounding variables.
Some studies find a small association
between PPHN and SSRI use, although
other studies do not.
The evidence regarding the risk of PPHN
due to in utero antidepressant exposure in
inconclusive.

Footnotes

CONFLICT OF INTEREST The authors declare that they not conflict of interest.

Contributor Information

Nancy Byatt, Psychiatrist, Psychosomatic Medicine, Women’s Mental Health Univ. of Massachusetts Medical School/UMass Memorial Medical Center 55 Lake Avenue North Worcester, MA 01655.

Kristina M. Deligiannidis, Depression Specialty Clinic Psychiatrist, Women’s Mental Health Specialty Clinic Univ. of Massachusetts Medical School/UMass Memorial Medical Center Center for Psychopharmacologic Research and Treatment 361 Plantation Street Worcester, MA 01605.

Marlene P. Freeman, Harvard Medical School/Massachusetts General Hospital Perinatal and Reproductive Psychiatry Program 185 Cambridge Street, 2nd Floor Boston, MA 02114.

REFERENCES

1. VESGA-LOPEZ O, BLANCO C, KEYES K, OLFSON M, GRANT BF, HASIN DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65:805–15. [PMC free article] [PubMed]
2. GAVIN NI, GAYNES BN, LOHR KN, MELTZER-BRODY S, GARTLEHNER G, SWINSON T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106:1071–83. [PubMed]
3. BORRI C, MAURI M, OPPO A, et al. Axis I psychopathology and functional impairment at the third month of pregnancy: Results from the Perinatal Depression-Research and Screening Unit (PND-ReScU) study. J Clin Psychiatry. 2008;69:1617–24. [PubMed]
4. RECK C, STRUBEN K, BACKENSTRASS M, et al. Prevalence, onset and comorbidity of postpartum anxiety and depressive disorders. Acta Psychiatr Scand. 2008;118:459–68. [PubMed]
5. BODNAR LM, WISNER KL, MOSES-KOLKO E, SIT DK, HANUSA BH. Prepregnancy body mass index, gestational weight gain, and the likelihood of major depressive disorder during pregnancy. J Clin Psychiatry. 2009;70:1290–6. [PMC free article] [PubMed]
6. FLYNN HA, CHERMACK ST. Prenatal alcohol use: the role of lifetime problems with alcohol, drugs, depression, and violence. J Stud Alcohol Drugs. 2008;69:500–9. [PubMed]
7. CRIPE SM, FREDERICK IO, QIU C, WILLIAMS MA. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatr Perinat Epidemiol. 2011;25:116–23. [PMC free article] [PubMed]
8. WISNER KL, ZARIN DA, HOLMBOE ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. AJ Psychiatry. 2000;157:1933–40. [PubMed]
9. WADHWA PD, SANDMAN CA, PORTO M, DUNKEL-SCHETTER C, GARITE TJ. The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. Am J Obstet Gynecol. 1993;169:858–65. [PubMed]
10. ISTVAN J. Stress, anxiety, and birth outcomes: a critical review of the evidence. Psychol Bull. 1986;100:331–48. [PubMed]
11. GROTE NK, BRIDGE JA, GAVIN AR, MELVILLE JL, IYENGAR S, KATON WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67:1012–24. [PMC free article] [PubMed]
12. SURI R, ALTSHULER LA, MINTZ J. Depression and the decision to abort. AJ Psychiatry. 2004;161:1502. [PubMed]
13. GOTLIB IH, WHIFFEN VE, WALLACE PM, MOUNT JH. Prospective investigation of postpartum depression: factors involved in onset and recovery. J Abnorm Psychol. 1991;100:122–32. [PubMed]
14. JABLENSKY AV, MORGAN V, ZUBRICK SR, BOWER C, YELLACHICH LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. AJ Psychiatry. 2005;162:79–91. [PubMed]
15. CHUNG TK, LAU TK, YIP AS, CHIU HF, LEE DT. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med. 2001;63:830–4. [PubMed]
16. FORMAN DR, O’HARA MW, STUART S, GORMAN LL, LARSEN KE, COY KC. Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev Psychopathol. 2007;19:585–602. [PubMed]
17. BRITTON JR. Infant temperament and maternal anxiety and depressed mood in the early postpartum period. Women Health. 2011;51:55–71. [PubMed]
18. SOHR-PRESTON SL, SCARAMELLA LV. Implications of timing of maternal depressive symptoms for early cognitive and language development. Clin Child Fam Psychol Rev. 2006;9:65–83. [PubMed]
19. DOWNEY G, COYNE JC. Children of depressed parents: an integrative review. Psychol Bull. 1990;108:50–76. [PubMed]
20. DEAVE T, HERON J, EVANS J, EMOND A. The impact of maternal depression in pregnancy on early child development. BJOG. 2008;115:1043–51. [PubMed]
21. PAULSON JF, KEEFE HA, LEIFERMAN JA. Early parental depression and child language development. J Child Psychol Psychiatry. 2009;50:254–62. [PubMed]
22. PILOWSKY DJ, WICKRAMARATNE PJ, RUSH AJ, et al. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry. 2006;67:126–36. [PubMed]
23. WEISSMAN MM, PILOWSKY DJ, WICKRAMARATNE PJ, et al. Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA. 2006;295:1389–98. [PubMed]
24. LINDAHL V, PEARSON JL, COLPE L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. 2005;8:77–87. [PubMed]
25. LOBEL M, CANNELLA DL, GRAHAM JE, DEVINCENT C, SCHNEIDER J, MEYER BA. Pregnancy-specific stress, prenatal health behaviors, and birth outcomes. Health Psychol. 2008;27:604–15. [PubMed]
26. BEYDOUN H, SAFTLAS AF. Physical and mental health outcomes of prenatal maternal stress in human and animal studies: a review of recent evidence. Paediatr Perinat Epidemiol. 2008;22:438–66. [PubMed]
27. BUSS C, DAVIS EP, MUFTULER LT, HEAD K, SANDMAN CA. High pregnancy anxiety during mid-gestation is associated with decreased gray matter density in 6-9-year-old children. Psychoneuroendocrinology. 2010;35:141–53. [PMC free article] [PubMed]
28. COHEN LS, ALTSHULER LL, HARLOW BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499–507. [PubMed]
29. BENNETT IM, MARCUS SC, PALMER SC, COYNE JC. Pregnancy-related discontinuation of antidepressants and depression care visits among Medicaid recipients. Psychiatr Serv. 2010;61:386–91. [PubMed]
30. HEMELS ME, EINARSON A, KOREN G, LANCTOT KL, EINARSON TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother. 2005;39:803–9. [PubMed]
31. RAHIMI R, NIKFAR S, ABDOLLAHI M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006;22:571–5. [PubMed]
32. EINARSON A, FATOYE B, SARKAR M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. AJ Psychiatry. 2001;158:1728–30. [PubMed]
33. EINARSON A, CHOI J, EINARSON TR, KOREN G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can. 2009;31:452–6. [PubMed]
34. NAKHAI-POUR HR, BROY P, BERARD A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ. 2010;182:1031–7. [PMC free article] [PubMed]
35. CHAMBERS CD, JOHNSON KA, DICK LM, FELIX RJ, JONES KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–5. [PubMed]
36. KULIN NA, PASTUSZAK A, SAGE SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609–10. [PubMed]
37. CHUN-FAI-CHAN B, KOREN G, FAYEZ I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932–6. [PubMed]
38. YARIS F, KADIOGLU M, KESIM M, et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol. 2004;19:235–8. [PubMed]
39. DJULUS J, KOREN G, EINARSON TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry. 2006;67:1280–4. [PubMed]
40. KALLEN B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312–6. [PubMed]
41. REIS M, KALLEN B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40:1723–33. [PubMed]
42. LUND N, PEDERSEN LH, HENRIKSEN TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009;163:949–54. [PubMed]
43. SIMON GE, CUNNINGHAM ML, DAVIS RL. Outcomes of prenatal antidepressant exposure. AJ Psychiatry. 2002;159:2055–61. [PubMed]
44. SURI R, ALTSHULER L, HELLEMANN G, BURT VK, AQUINO A, MINTZ J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. AJ Psychiatry. 2007;164:1206–13. [PubMed]
45. CROEN LA, GRETHER JK, YOSHIDA CK, ODOULI R, HENDRICK V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68:1104–12. [PubMed]
46. GENTILE S, GALBALLY M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord. 2011;128:1–9. [PubMed]
47. Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57:1–5. [PubMed]
48. HOFFMAN JI, KAPLAN S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890–900. [PubMed]
49. RELLER MD, STRICKLAND MJ, RIEHLE-COLARUSSO T, MAHLE WT, CORREA A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807–13. [PMC free article] [PubMed]
50. KALLEN B, NILSSON E, OLAUSSON PO. Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol. 2011;67:839–45. [PubMed]
51. KALLEN BA, OTTERBLAD OLAUSSON P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79:301–8. [PubMed]
52. WARBURTON W, HERTZMAN C, OBERLANDER TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010;121:471–9. [PubMed]
53. MALM H, KLAUKKA T, NEUVONEN PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106:1289–96. [PubMed]
54. PASTUSZAK A, SCHICK-BOSCHETTO B, ZUBER C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac) JAMA. 1993;269:2246–8. [PubMed]
55. HENDRICK V, SMITH LM, SURI R, HWANG S, HAYNES D, ALTSHULER L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003;188:812–5. [PubMed]
56. GOLDSTEIN DJ, CORBIN LA, SUNDELL KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol. 1997;89:713–8. [PubMed]
57. ERICSON A, KALLEN B, WIHOLM B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999;55:503–8. [PubMed]
58. SIVOJELEZOVA A, SHUHAIBER S, SARKISSIAN L, EINARSON A, KOREN G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005;193:2004–9. [PubMed]
59. HALLBERG P, SJOBLOM V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol. 2005;25:59–73. [PubMed]
60. ALWAN S, REEFHUIS J, RASMUSSEN SA, OLNEY RS, FRIEDMAN JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356:2684–92. [PubMed]
61. MERLOB P, BIRK E, SIROTA L, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol. 2009;85:837–41. [PubMed]
62. LOUIK C, LIN AE, WERLER MM, HERNANDEZ-DIAZ S, MITCHELL AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675–83. [PubMed]
63. BIRNDORF CA, MADDEN A, PORTERA L, LEON AC. Psychiatric symptoms, functional impairment, and receptivity toward mental health treatment among obstetrical patients. Int J Psychiatry Med. 2001;31:355–65. [PubMed]
64. WOGELIUS P, NORGAARD M, GISLUM M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17:701–4. [PubMed]
65. DIAV-CITRIN O, SHECHTMAN S, WEINBAUM D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66:695–705. [PubMed]
66. COLE JA, EPHROSS SA, COSMATOS IS, WALKER AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1075–85. [PubMed]
67. WILLIAMS M, WOOLTORTON E. Paroxetine (Paxil) and congenital malformations. CMAJ. 2005;173:1320–1. [PMC free article] [PubMed]
68. EINARSON A, KOREN G. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Can Fam Physician. 2006;52:593–4. [PMC free article] [PubMed]
69. BERARD A, RAMOS E, REY E, BLAIS L, ST-ANDRE M, ORAICHI D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80:18–27. [PubMed]
70. WURST KE, POOLE C, EPHROSS SA, OLSHAN AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88:159–70. [PubMed]
71. BAR-OZ B, EINARSON T, EINARSON A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther. 2007;29:918–26. [PubMed]
72. BAKKER MK, KERSTJENS-FREDERIKSE WS, BUYS CH, DE WALLE HE, DE JONG-VAN DEN BERG LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88:94–100. [PubMed]
73. MALM H, ARTAMA M, GISSLER M, RITVANEN A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118:111–20. [PubMed]
74. EINARSON A, PISTELLI A, DESANTIS M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. AJ Psychiatry. 2008;165:749–52. [PubMed]
75. GENTILE S, BELLANTUONO C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry. 2009;70:414–22. [PubMed]
76. BAKKER MK, DE WALLE HE, WILFFERT B, DE JONG-VAN DEN BERG LT. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiol Drug Saf. 2010;19:808–13. [PubMed]
77. OBERLANDER TF, WARBURTON W, MISRI S, RIGGS W, AGHAJANIAN J, HERTZMAN C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83:68–76. [PubMed]
78. KORNUM JB, NIELSEN RB, PEDERSEN L, MORTENSEN PB, NORGAARD M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol. 2010;2:29–36. [PMC free article] [PubMed]
79. PEDERSEN LH, HENRIKSEN TB, VESTERGAARD M, OLSEN J, BECH BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569. [PMC free article] [PubMed]
80. WEN SW, YANG Q, GARNER P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194:961–6. [PubMed]
81. EINARSON A, CHOI J, EINARSON TR, KOREN G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009;54:242–6. [PubMed]
82. EINARSON A, CHOI J, KOREN G, EINARSON T. Outcomes of infants exposed to multiple antidepressants during pregnancy: results of a cohort study. J Popul Ther Clin Pharmacol. 2011;18:e390–6. [PubMed]
83. RAMOS E, ST-ANDRE M, REY E, ORAICHI D, BERARD A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry. 2008;192:344–50. [PubMed]
84. WISNER KL, SIT DK, HANUSA BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. AJ Psychiatry. 2009;166:557–66. [PubMed]
85. KLIEGER-GROSSMANN C, WEITZNER B, PANCHAUD A, et al. Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study. J Clin Pharmacol. 2011 [PubMed]
86. ADDIS A, KOREN G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med. 2000;30:89–94. [PubMed]
87. EINARSON TR, EINARSON A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14:823–7. [PubMed]
88. O’BRIEN L, EINARSON TR, SARKAR M, EINARSON A, KOREN G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can. 2008;30:696–701. [PubMed]
89. LENNESTAL R, KALLEN B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607–13. [PubMed]
90. EINARSON A, BONARI L, VOYER-LAVIGNE S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry. 2003;48:106–10. [PubMed]
91. GLAXOSMITHKLINE The Bupropion Pregnancy Registry Final Report. 2008 Available from: http://pregnancyregistry.gsk.com/documents/bup_report_final_2008.pdf.
92. ALWAN S, REEFHUIS J, BOTTO LD, RASMUSSEN SA, CORREA A, FRIEDMAN JM. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203:52 e1–6. [PubMed]
93. COLE JA, MODELL JG, HAIGHT BR, COSMATOS IS, STOLER JM, WALKER AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:474–84. [PubMed]
94. WEBSTER PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet. 1973;2:318–9. [PubMed]
95. MOSES-KOLKO EL, BOGEN D, PEREL J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–83. [PubMed]
96. NORDENG H, YSTROM E, EINARSON A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol. 2010;66:207–14. [PubMed]
97. SPENCER MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993;92:721–2. [PubMed]
98. DAHL ML, OLHAGER E, AHLNER J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry. 1997;171:391–2. [PubMed]
99. NIJHUIS IJ, KOK-VAN ROOIJ GW, BOSSCHAART AN. Withdrawal reactions of a premature neonate after maternal use of paroxetine. Arch Dis Child Fetal Neonatal Ed. 2001;84:F77. [PMC free article] [PubMed]
100. SANZ EJ, DE-LAS-CUEVAS C, KIURU A, BATE A, EDWARDS R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482–7. [PubMed]
101. LAINE K, HEIKKINEN T, EKBLAD U, KERO P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720–6. [PubMed]
102. COSTEI AM, KOZER E, HO T, ITO S, KOREN G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129–32. [PubMed]
103. ALEHAN F, SAYGI S, TARCAN A, GURAKAN B. Prolonged neonatal complications after in utero exposure to fluoxetine. J Matern Fetal Neonatal Med. 2008;21:921–3. [PubMed]
104. OBERLANDER TF, MISRI S, FITZGERALD CE, KOSTARAS X, RURAK D, RIGGS W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65:230–7. [PubMed]
105. OBERLANDER TF, WARBURTON W, MISRI S, AGHAJANIAN J, HERTZMAN C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898–906. [PubMed]
106. KNOPPERT DC, NIMKAR R, PRINCIPI T, YUEN D. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit. 2006;28:5–7. [PubMed]
107. KWON P, LEFKOWITZ W. Poor neonatal adaptation in term infant. Fluoxetine toxicity. Pediatr Ann. 2008;37:131–3. [PubMed]
108. MHANNA MJ, BENNET JB, 2ND, IZATT SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics. 1997;100:158–9. [PubMed]
109. MOHAN CG, MOORE JJ. Fluoxetine toxicity in a preterm infant. J Perinatol. 2000;20:445–6. [PubMed]
110. ANBU AT, THEODORE A. Fluoxetine withdrawal syndrome in the newborn. Indian Pediatr. 2006;43:66–9. [PubMed]
111. KENT LS, LAIDLAW JD. Suspected congenital sertraline dependence. Br J Psychiatry. 1995;167:412–3. [PubMed]
112. BOUCHER N, BAIRAM A, BEAULAC-BAILLARGEON L. A new look at the neonate’s clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol. 2008;28:334–9. [PubMed]
113. HERBST F, GORTNER L. [Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy?] Z Geburtshilfe Neonatol. 2003;207:232–4. [PubMed]
114. DE MOOR RA, MOURAD L, TER HAAR J, EGBERTS AC. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy] Ned Tijdschr Geneeskd. 2003;147:1370–2. [PubMed]
115. COHEN LS, HELLER VL, BAILEY JW, GRUSH L, ABLON JS, BOUFFARD SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 2000;48:996–1000. [PubMed]
116. LEVINSON-CASTIEL R, MERLOB P, LINDER N, SIROTA L, KLINGER G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173–6. [PubMed]
117. FERREIRA E, CARCELLER AM, AGOGUE C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119:52–9. [PubMed]
118. GALBALLY M, LEWIS AJ, LUM J, BUIST A. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry. 2009;43:846–54. [PubMed]
119. SURI R, ALTSHULER L, HENDRICK V, RASGON N, LEE E, MINTZ J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health. 2004;7:193–200. [PubMed]
120. MASCHI S, CLAVENNA A, CAMPI R, SCHIAVETTI B, BERNAT M, BONATI M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG. 2008;115:283–9. [PubMed]
121. HIBBARD JU, WILKINS I, SUN L, et al. Respiratory morbidity in late preterm births. JAMA. 2010;304:419–25. [PMC free article] [PubMed]
122. ADMINISTRATION. UFAD [cited 2011 12/22/11];FDA Medwatch Drug Alert on Effexor (venlafaxine HCL) and Effecor XR (venlafaxine HCL) 2004 Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154975.htm.
123. HERNANDEZ-MARTINEZ C, ARIJA V, BALAGUER A, CAVALLE P, CANALS J. Do the emotional states of pregnant women affect neonatal behaviour? Early Hum Dev. 2008;84:745–50. [Research Support, Non-U.S. Gov’t] [PubMed]
124. STEINHORN RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med. 2010;11:S79–84. [PMC free article] [PubMed]
125. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS) J Pediatr. 2000;136:611–7. [PubMed]
126. DAVIDSON D, BAREFIELD ES, KATTWINKEL J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I NO/PPHN Study Group. Pediatrics. 1998;101:325–34. [PubMed]
127. GREENOUGH A, KHETRIWAL B. Pulmonary hypertension in the newborn. Paediatr Respir Rev. 2005;6:111–6. [PubMed]
128. OCCHIOGROSSO M, OMRAN SS, ALTEMUS M. Persistent Pulmonary Hypertension of the Newborn and Selective Serotonin Reuptake Inhibitors: Lessons From Clinical and Translational Studies. AJ Psychiatry. 2011 [PubMed]
129. GROUP NINOS Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS) J Pediatr. 2000;136:611–7. [PubMed]
130. KOREN G, BOUCHER N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation--Motherisk Update 2008. Can J Clin Pharmacol. 2009;16:e66–7. [PubMed]
131. BOUCHER N, KOREN G, BEAULAC-BAILLARGEON L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit. 2009;31:404–9. [PubMed]
132. OBERLANDER TF, WARBURTON W, MISRI S, AGHAJANIAN J, HERTZMAN C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192:338–43. [PubMed]
133. EDDAHIBI S, RAFFESTIN B, HAMON M, ADNOT S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med. 2002;139:194–201. [PubMed]
134. FORNARO E, LI D, PAN J, BELIK J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med. 2007;176:1035–40. [PubMed]
135. DAKSHINAMURTI S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2005;39:492–503. [PubMed]
136. EDDAHIBI S, HUMBERT M, FADEL E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108:1141–50. [PMC free article] [PubMed]
137. OBERLANDER TF, BONAGURO RJ, MISRI S, PAPSDORF M, ROSS CJ, SIMPSON EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry. 2008;13:65–73. [PubMed]
138. CHAMBERS CD, HERNANDEZ-DIAZ S, VAN MARTER LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–87. [PubMed]
139. KALLEN B, OLAUSSON PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17:801–6. [PubMed]
140. HERITAGE CK, CUNNINGHAM MD. Association of elective repeat cesarean delivery and persistent pulmonary hypertension of the newborn. Am J Obstet Gynecol. 1985;152:627–9. [PubMed]
141. HERNANDEZ-DIAZ S, VAN MARTER LJ, WERLER MM, LOUIK C, MITCHELL AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics. 2007;120:e272–82. [PubMed]
142. KIELER H, ARTAMA M, ENGELAND A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2011;344:d8012. [PubMed]
143. ANDRADE SE, MCPHILLIPS H, LOREN D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18:246–52. [PubMed]
144. WICHMAN CL, MOORE KM, LANG TR, ST SAUVER JL, HEISE RH, JR., WATSON WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84:23–7. [PMC free article] [PubMed]
145. WILSON KL, ZELIG CM, HARVEY JP, CUNNINGHAM BS, DOLINSKY BM, NAPOLITANO PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2010;28:19–24. [PubMed]
146. ADMINISTRATION USFAD FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 2011. 12/4/11 ed.
147. KESZLER M, CARBONE MT, COX C, SCHUMACHER RE. Severe respiratory failure after elective repeat cesarean delivery: a potentially preventable condition leading to extracorporeal membrane oxygenation. Pediatrics. 1992;89:670–2. [PubMed]
148. LEVINE EM, GHAI V, BARTON JJ, STROM CM. Mode of delivery and risk of respiratory diseases in newborns. Obstet Gynecol. 2001;97:439–42. [PubMed]
149. REECE EA, MOYA F, YAZIGI R, HOLFORD T, DUNCAN C, EHRENKRANZ RA. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet Gynecol. 1987;70:696–700. [PubMed]
150. GENTILE S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand. 2011;123:266–75. [Review] [PubMed]
151. SERVICES DOHAH In: Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling. Administration FaD, editor. 2008.
152. NULMAN I, ROVET J, STEWART DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. AJ Psychiatry. 2002;159:1889–95. [PubMed]
153. SIT DK, PEREL JM, HELSEL JC, WISNER KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008;69:652–8. [PMC free article] [PubMed]
154. HOSTETTER A, STOWE ZN, STRADER JR, JR., MCLAUGHLIN E, LLEWELLYN A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety. 2000;11:51–7. [PubMed]
155. YONKERS KA, WISNER KL, STEWART DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31:403–13. [PMC free article] [PubMed]
156. ZESKIND PS, STEPHENS LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368–75. [PubMed]
157. RAMPONO J, SIMMER K, ILETT KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42:95–100. [PubMed]
158. SURI R, HELLEMANN G, STOWE ZN, COHEN LS, AQUINO A, ALTSHULER LL. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry. 2011;72:1002–7. [PMC free article] [PubMed]
159. SIT D, PEREL JM, WISNIEWSKI SR, HELSEL JC, LUTHER JF, WISNER KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry. 2011;72:994–1001. [PMC free article] [PubMed]
160. WILSON KL, ZELIG CM, HARVEY JP, CUNNINGHAM BS, DOLINSKY BM, NAPOLITANO PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011;28:19–24. [PubMed]